Literature DB >> 8443912

The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.

M Ruzicka1, B Yuan, E Harmsen, F H Leenen.   

Abstract

BACKGROUND: The degree of cardiac hypertrophy is not only load dependent: Among other factors, the renin-angiotensin system may play a role in the regulation of cardiac myocyte growth. METHODS AND
RESULTS: To evaluate the role of the renin-angiotensin system in volume overload-induced cardiac hypertrophy, we assessed: 1) the time course of changes in cardiac hemodynamics, cardiac anatomy, and plasma and cardiac renin activity in response to volume overload induced by two sizes of abdominal aortocaval shunt and 2) the effects of chronic treatment with an angiotensin converting enzyme inhibitor (ACEI) versus an angiotensin II receptor blocker on hemodynamics and cardiac hypertrophy. Drug treatment started 3 days before shunt surgery. An increase in left ventricular end-diastolic pressure (LVEDP) and the development of right ventricular (RV) and left ventricular (LV) eccentric hypertrophy in response to volume overload occurred within the first week after induction of the shunt. Plasma renin activity (PRA) and cardiac renin activity peaked shortly after induction of the shunt. During the chronic phase, LVEDP and PRA decreased somewhat but remained significantly elevated up to 7 weeks after shunt surgery. Cardiac renin activity returned toward normal within 4 weeks after surgery. Treatment with the ACEI enalapril caused only a modest decrease in LV internal diameter but did not affect increases in LV and RV weights in response to volume overload despite a major decrease in LVEDP after chronic treatment. In contrast, treatment with the angiotensin II receptor blocker losartan, which had similar effects on cardiac and peripheral hemodynamics, prevented dilation of the LV after 7 days and attenuated the dilation of the LV after 28 days. Moreover, increases in LV and RV weights were significantly attenuated by losartan.
CONCLUSIONS: The development of volume overload-induced cardiac hypertrophy is associated with significant increases in PRA and cardiac renin activity shortly after induction of an aortocaval shunt. Whereas the two blockers of the renin-angiotensin system decreased LVEDP to a similar extent, only the angiotensin II receptor blocker blunted the hypertrophic response of the heart to volume overload, which is indicative for other than hemodynamic determinants of the cardiac hypertrophic response. One trophic factor may be cardiac angiotensin II generated via an angiotensin II-forming enzyme resistant to ACEI and possibly activated by cardiac volume overload.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443912     DOI: 10.1161/01.cir.87.3.921

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.

Authors:  L Červenka; V Melenovský; Z Husková; A Sporková; M Bürgelová; P Škaroupková; S H Hwang; B D Hammock; J D Imig; J Sadowski
Journal:  Physiol Res       Date:  2015-06-05       Impact factor: 1.881

2.  Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin.

Authors:  Elie R Chemaly; Soojeong Kang; Shihong Zhang; LaTronya McCollum; Jiqiu Chen; Ludovic Bénard; K-Raman Purushothaman; Roger J Hajjar; Djamel Lebeche
Journal:  J Physiol       Date:  2013-09-09       Impact factor: 5.182

Review 3.  The renin-angiotensin system and the heart: beyond 2000.

Authors:  T Morgan; H R Brunner
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats.

Authors:  Vojtech Melenovsky; Jan Benes; Petra Skaroupkova; David Sedmera; Hynek Strnad; Michal Kolar; Cestmir Vlcek; Jiri Petrak; Jiri Benes; Frantisek Papousek; Olena Oliyarnyk; Ludmila Kazdova; Ludek Cervenka
Journal:  Mol Cell Biochem       Date:  2011-04-05       Impact factor: 3.396

5.  Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.

Authors:  N Makino; M Sugano; T Hata; S Taguchi; T Yanaga
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

6.  Relation of cardiovascular risk factors to right ventricular structure and function as determined by magnetic resonance imaging (results from the multi-ethnic study of atherosclerosis).

Authors:  Harjit Chahal; Craig Johnson; Harikrishna Tandri; Aditya Jain; W Gregory Hundley; R Graham Barr; Steven M Kawut; Joao A C Lima; David A Bluemke
Journal:  Am J Cardiol       Date:  2010-05-13       Impact factor: 2.778

7.  Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy.

Authors:  H Kobori; A Ichihara; Y Miyashita; M Hayashi; T Saruta
Journal:  J Endocrinol       Date:  1999-01       Impact factor: 4.286

8.  Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat.

Authors:  L A Brown; D J Nunez; M R Wilkins
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

Review 9.  Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.

Authors:  Zaid Abassi; Ilia Goltsman; Tony Karram; Joseph Winaver; Aaron Hoffman
Journal:  J Biomed Biotechnol       Date:  2011-01-11

10.  Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload.

Authors:  Melissa R Dent; Nina Aroutiounova; N S Dhalla; P S Tappia
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.